Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATFurniture, Fixtures and OtherLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

Plus Therapeutics (PSTV) EBIAT (2016 - 2025)

Plus Therapeutics has reported EBIAT over the past 15 years, most recently at -$5.7 million for Q4 2025.

  • Quarterly EBIAT fell 46.04% to -$5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$22.4 million through Dec 2025, down 72.39% year-over-year, with the annual reading at -$22.4 million for FY2025, 72.6% down from the prior year.
  • EBIAT was -$5.7 million for Q4 2025 at Plus Therapeutics, down from -$4.4 million in the prior quarter.
  • Over five years, EBIAT peaked at $5.2 million in Q2 2025 and troughed at -$17.4 million in Q1 2025.
  • The 5-year median for EBIAT is -$3.8 million (2023), against an average of -$4.1 million.
  • The largest YoY upside for EBIAT was 275.2% in 2025 against a maximum downside of 433.61% in 2025.
  • A 5-year view of EBIAT shows it stood at -$3.7 million in 2021, then plummeted by 51.93% to -$5.7 million in 2022, then surged by 32.66% to -$3.8 million in 2023, then fell by 2.44% to -$3.9 million in 2024, then plummeted by 46.04% to -$5.7 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's EBIAT are -$5.7 million (Q4 2025), -$4.4 million (Q3 2025), and $5.2 million (Q2 2025).